The company is adjusting revenue guidance for full fiscal year 2024 to $137M to $147M previously $145M and $165M- Consensus for FY24 revenue is $154.09M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CDMO:
- Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
- CDMO Earnings this Week: How Will it Perform?
- Alkermes, Armstrong World, National Healthcare, PJT Partners to join S&P 600
- Avid Bioservices partners with CIRM to provide CDMO services for CGT programs
- Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
